All Clinical Trials in Canada

A listing of 3904 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

Canada

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

NCT03816319

Recruiting

This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to treatment (refractory). TAK-243 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: Moffitt Cancer Center, Tampa, Florida +3 locations

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

Learn More ›

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868

Recruiting

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: Local Institution - 0303, Hot Springs, Arkansas +241 locations

Local Institution - 0303, Hot Springs, Arkansas

Local Institution - 0307, Cerritos, California

Local Institution - 0308, Cerritos, California

Local Institution - 0309, Cerritos, California

Local Institution - 0311, Long Beach, California

Local Institution - 0290, Los Angeles, California

Local Institution - 0283, Los Angeles, California

Local Institution - 0328, Whittier, California

Local Institution - 0289, Aurora, Colorado

Local Institution - 0304, Newark, Delaware

Local Institution - 0282, Miami, Florida

Local Institution - 0296, Pembroke Pines, Florida

Local Institution - 0294, Atlanta, Georgia

Local Institution - 0278, Chicago, Illinois

Local Institution - 0280, Chicago, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Local Institution - 0324, O'Fallon, Illinois

Local Institution - 0286, Covington, Louisiana

Local Institution - 0288, Boston, Massachusetts

Local Institution - 0287, Boston, Massachusetts

Local Institution - 0313, Minneapolis, Minnesota

Local Institution - 0284, Kansas City, Missouri

Local Institution - 0312, New York, New York

Local Institution - 0279, New York, New York

Clinical Research Alliance, Westbury, New York

Local Institution - 0285, White Plains, New York

Local Institution - 0276, Durham, North Carolina

Local Institution - 0316, Eugene, Oregon

Local Institution - 0310, Philadelphia, Pennsylvania

Local Institution - 0281, Greenville, South Carolina

Local Institution - 0315, Austin, Texas

Local Institution - 0314, Houston, Texas

Local Institution - 0305, Tyler, Texas

Local Institution - 0277, Midlothian, Virginia

Local Institution - 0301, Roanoke, Virginia

Local Institution - 0302, Winchester, Virginia

Local Institution - 0345, Buenas Aires, Buenos Aires

Local Institution - 0011, Ciudad autónoma de Buenos Aires, Buenos Aires

Local Institution - 0214, ABB, Ciudad Autónoma De Buenos Aires

Local Institution - 0143, Cordoba, Córdoba

Local Institution - 0137, Río Cuarto, Córdoba

Local Institution - 0142, Rosario, Santa Fe

Local Institution - 0317, Buenos Aires, Not set

Local Institution - 0346, Buenos Aires, Not set

Local Institution - 0012, Ciudad Autónoma de Buenos Aires, Not set

Local Institution - 0035, Brisbane, Queensland

Local Institution - 0197, Ballarat Central, Victoria

Local Institution - 0031, Heidelberg, Victoria

Local Institution - 0274, Melbourne, Victoria

Local Institution - 0028, Subiaco, Western Australia

Local Institution - 0292, Graz, Steiermark

Local Institution - 0268, Innsbruck, Tirol

Local Institution - 0267, Salzburg, Not set

Local Institution - 0270, St. Polten, Not set

Local Institution - 0269, Wien, Not set

Local Institution - 0187, Manaus, Amazonas

Local Institution - 0147, Fortaleza, Ceará

Local Institution - 0157, Vitória, Espírito Santo

Local Institution - 0199, Porto Alegre, Rio Grande Do Sul

Local Institution - 0164, São José do Rio Preto, São Paulo

Local Institution - 0153, Rio de Janeiro, Not set

Local Institution - 0144, São Paulo, Not set

Local Institution - 0149, São Paulo, Not set

Local Institution - 0218, Kelowna, British Columbia

Local Institution - 0217, Victoria, British Columbia

Local Institution - 0265, Ottawa, Ontario

Local Institution - 0215, Montréal, Quebec

Local Institution - 0219, Montréal, Quebec

Local Institution - 0350, Saint-Jerome, Quebec

Local Institution - 0216, Sherbrooke, Quebec

Local Institution - 0138, Santiago, Región Metropolitana De Santiago

Local Institution - 0021, Santiago, Región Metropolitana De Santiago

Local Institution - 0017, Santiago, Región Metropolitana De Santiago

Local Institution - 0018, Santiago, Región Metropolitana De Santiago

Local Institution - 0016, Viña del Mar, Valparaíso

Local Institution - 0195, Medellín, Antioquia

Local Institution - 0201, Rionegro, Antioquia

Local Institution - 0194, Barranquilla, Atlántico

Local Institution - 0182, Puerto Colombia, Atlántico

Local Institution - 0181, Montería, COR

Local Institution - 0327, Bogota, Cundinamarca

Local Institution - 0183, Cali, Valle Del Cauca

Local Institution - 0349, Medellin, Not set

Local Institution - 0089, Bordeaux, Aquitaine

Local Institution - 0272, Dijon, Côte-d'Or

Local Institution - 0098, Toulouse, Haute-Garonne

Local Institution - 0095, Montpellier, Hérault

Local Institution - 0099, Rennes, Ille-et-Vilaine

Local Institution - 0092, Saint Herblain, Loire-Atlantique

Local Institution - 0091, Reims, Marne

Local Institution - 0097, Villejuif, Paris

Local Institution - 0093, Marseille, Provence-Alpes-Côte-d'Azur

Local Institution - 0096, Clermont-Ferrand, Puy-de-Dôme

Local Institution - 0090, Lyon, Rhône-Alpes

Local Institution - 0094, Lille, Not set

Local Institution - 0088, Paris, Not set

Local Institution - 0320, Esslingen, Baden-Württemberg

Local Institution - 0256, Augsburg, Bayern

Local Institution - 0271, München, Bayern

Local Institution - 0306, Frankfurt, Hessen

Local Institution - 0333, Langen, Hessen

Local Institution - 0257, Hannover, Niedersachsen

Local Institution - 0293, Düsseldorf, Nordrhein-Westfalen

Local Institution - 0263, Essen, Nordrhein-Westfalen

Local Institution - 0254, Leipzig, Sachsen

Local Institution - 0255, Lübeck, Schleswig-Holstein

Local Institution - 0261, Berlin, Not set

Local Institution - 0260, Berlin, Not set

Local Institution - 0259, Bonn, Not set

Local Institution - 0258, Dresden, Not set

Local Institution - 0262, Heidelberg, Not set

Local Institution - 0291, Ulm, Not set

Local Institution - 0042, Athens, Attikí

Local Institution - 0038, Athens, Attikí

Local Institution - 0086, Heraklion, Irakleío

Local Institution - 0043, Athens, Not set

Local Institution - 0266, New Delhi, Delhi

Local Institution - 0206, New Delhi, Delhi

Local Institution - 0131, Mumbai, Maharashtra

Local Institution - 0134, Nagpur, Maharashtra

Local Institution - 0125, Chennai, Tamil Nadu

Local Institution - 0130, Hyderabad, Telangana

Local Institution - 0133, Varanasi, Uttar Pradesh

Local Institution - 0352, New Delhi, Not set

Local Institution - 0186, Petah Tikva, HaMerkaz

Local Institution - 0044, Ramat Gan, HaMerkaz

Local Institution - 0048, Hadera, HaTsafon

Local Institution - 0123, Haifa, HaTsafon

Local Institution - 0047, Jerusalem, Yerushalayim

Local Institution - 0051, Napoli, Campania

Local Institution - 0049, Bologna, Emilia-Romagna

Local Institution - 0057, Aviano, Friuli-Venezia Giulia

Local Institution - 0054, Genova, Liguria

Local Institution - 0053, Pontedera, Pisa

Local Institution - 0055, Prato, Toscana

Local Institution - 0052, Milano, Not set

Local Institution - 0058, Napoli, Not set

Local Institution - 0061, Novara, Not set

Local Institution - 0056, Padova, Not set

Local Institution - 0062, Roma, Not set

Local Institution - 0236, Nagoya, Aichi

Local Institution - 0230, Chiba-shi, Chiba

Local Institution - 0240, Matsuyama, Ehime

Local Institution - 0226, Otashi, Gunma

Local Institution - 0222, Sapporo, Hokkaido

Local Institution - 0232, Kanazawa, Ishikawa

Local Institution - 0234, Isehara, Kanagawa

Local Institution - 0237, Yokohama, Kanagawa

Local Institution - 0246, Tsu, Mie

Local Institution - 0223, Sendai-shi, Miyagi

Local Institution - 0238, Suita, Osaka

Local Institution - 0227, Hidaka, Saitama

Local Institution - 0224, Ina-machi, Saitama

Local Institution - 0231, Bunkyo-ku, Tokyo

Local Institution - 0229, Chuo-ku, Tokyo

Local Institution - 0228, Koto, Tokyo

Local Institution - 0245, Shinagawa, Tokyo

Local Institution - 0233, Shinjuku-ku, Tokyo

Local Institution - 0242, Fukuoka, Not set

Local Institution - 0225, Fukushima, Not set

Local Institution - 0243, Hiroshima, Not set

Local Institution - 0244, Kagoshima, Not set

Local Institution - 0235, Kyoto, Not set

Local Institution - 0241, Okayama, Not set

Local Institution - 0239, Osaka, Not set

Local Institution - 0066, Goyang-si, Kyǒnggi-do

Local Institution - 0067, Seongnam, Kyǒnggi-do

Local Institution - 0068, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0063, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0071, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0064, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0065, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0069, Daegu, Taegu-Kwangyǒkshi

Local Institution - 0264, Tijuana, Baja California

Local Institution - 0177, Mexico City, DIF

Local Institution - 0329, Mexico City, Distrito Federal

Local Institution - 0178, Guadalajara, Jalisco

Local Institution - 0175, Monterrey, Nuevo León

Local Institution - 0176, Monterrey, Nuevo León

Local Institution - 0173, Oaxaca de Juarez, Oaxaca

Local Institution - 0179, Merida, Yucatán

Local Institution - 0174, Chihuahua, Not set

Local Institution - 0074, Biala Podlaska, Lubelskie

Local Institution - 0072, Warszawa, Mazowieckie

Local Institution - 0220, Warszawa, Mazowieckie

Local Institution - 0076, Opole, Opolskie

Local Institution - 0189, Skórzewo, Wielkopolskie

Local Institution - 0221, Łódź, Łódzkie

Local Institution - 0198, Lisbon, Lisboa

Local Institution - 0106, Lisbon, Lisboa

Local Institution - 0109, Lisbon, Lisboa

Local Institution - 0124, Coimbra, Not set

Local Institution - 0141, Lisboa, Not set

Local Institution - 0111, Porto, Not set

Local Institution - 0253, Porto, Not set

Local Institution - 0212, Bistrita, Bistrița-Năsăud

Local Institution - 0213, Bucharest, București

Local Institution - 0079, Florești, Cluj

Local Institution - 0078, Craiova, Dolj

Local Institution - 0084, Ploiești, Prahova

Local Institution - 0211, Dumbravita, Timiș

Local Institution - 0085, Timișoara, Timiș

Local Institution - 0083, București, Not set

Local Institution - 0077, Cluj, Not set

Local Institution - 0081, Iași, Not set

Local Institution - 0080, Iași, Not set

Local Institution - 0351, East London, Eastern Cape

Local Institution - 0342, Parktown, Gauteng

Local Institution - 0336, Pretoria, Gauteng

Local Institution - 0341, Pretoria, Gauteng

Local Institution - 0340, Soweto, Gauteng

Local Institution - 0105, A Coruña, A Coruña [La Coruña]

Local Institution - 0100, Elche, Alicante

Local Institution - 0102, Barcelona, Barcelona [Barcelona]

Local Institution - 0172, Hospitalet, Barcelona [Barcelona]

Local Institution - 0140, Barcelona, Catalunya [Cataluña]

Local Institution - 0139, San Sebastian, Gipuzkoa

Local Institution - 0104, Madrid, Madrid, Comunidad De

Local Institution - 0108, Madrid, Madrid, Comunidad De

Local Institution - 0101, Malaga, Málaga

Local Institution - 0210, Valencia, Valenciana, Comunitat

Local Institution - 0107, Madrid, Not set

Local Institution - 0103, Sevilla, Not set

Local Institution - 0252, Malmö, Skåne Län [se-12]

Local Institution - 0026, Stockholm, Stockholms Län [se-01]

Local Institution - 0025, Uppsala, Uppsala Län [se-03]

Local Institution - 0024, Örebro, Örebro Län [se-18]

Local Institution - 0247, Linköping, Östergötlands Län [se-05]

Local Institution - 0250, st.Gallen, Sankt Gallen

Local Institution - 0249, Lausanne, Vaud

Local Institution - 0251, Zürich, Not set

Local Institution - 0323, Abu Dhabi, Abū Z̧aby

Local Institution - 0318, Abu Dhabi, Abū Z̧aby

Local Institution - 0322, Al Ain, Abū Z̧aby

Local Institution - 0319, Abu Dhabi, Not set

Local Institution - 0208, Truro, England

Local Institution - 0204, London, London, City Of

Local Institution - 0209, London, London, City Of

Local Institution - 0171, Belfast, Not set

Local Institution - 0004, London, Not set

Local Institution - 0001, Manchester, Not set

Local Institution - 0006, Nottingham, Not set

Conditions: Breast Neoplasms

Learn More ›

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

NCT06764316

Recruiting

In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY 3547926 for people with advanced HCC and look at the way the body absorbs and distributes the drug. The study drug, BAY 3547926, delivers a radioactive agent to cancer cells. The radioactive agent em... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: az Groeninge - Digestive Oncology, Kortrijk, Not set +9 locations

Conditions: Hepatocellular Carcinoma

Learn More ›

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797

Recruiting

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.

Gender:

ALL

Ages:

10 years and above

Trial Updated:

07/23/2025

Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +59 locations

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

University of California Los Angeles Rheumatology, Westwood, California

University of Miami Hospital and Clinics, Miami, Florida

The John Hopkins Hospital, Baltimore, Maryland

Maryland Oncology Hematology- Columbia, Rockville, Maryland

Tufts Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

St. Luke's Hospital, Duluth, Minnesota

Mosaic Life Care at Saint Joseph - Medical Center, Saint Joseph, Missouri

Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha, Nebraska

Overlook Medical Center, Summit, New Jersey

Columbia University Irving Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Nationwide Children's Hospital, Columbus, Ohio

Taylor Cancer Research Center, Maumee, Ohio

Toledo Clinic Cancer Center, Toledo, Ohio

Thomas Jefferson University, Philadelphia, Pennsylvania

Lifespan Cancer Institute - Rhode Island Hospital, Providence, Rhode Island

Baylor Scott & White Research Institute, Dallas, Texas

Baylor Scott & White Medical Center, Temple, Texas

University of Washington School of Medicine, Seattle, Washington

West Virginia University Health Sciences Campus, Morgantown, West Virginia

Newcastle Private Hospital, New Lambton Heights, New South Wales

Orange Health Service, Orange, New South Wales

Sydney Children's Hospital Network - Randwick, Randwick, New South Wales

The Alfred, Melbourne, Victoria

Sunny brook Health Sciences Centre- Bayview Campus, Toronto, Ontario

Centre Hospitalier Universitaire Sainte-Justine, Montréal, Quebec

Institut Bergonie, Bordeaux Cedex, Aquitaine

Hôpital Nord de Marseille, Marseille, Bouches-du-Rhône

Hôpital Morvan, Brest, Finistère

Hôpital Universitaire Pitié Salpêtrière, Paris, Ile-de-France

Institut de Cancerologie de l'Ouest- Angers, Angers, Pays De La Loire

Gustave Roussy, Villejuif, Val-de-Marne

Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, Not set

Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg

Krankenhaus Nordwest, Frankfurt, Hessen

Charité - Universitätsmedizin Berlin, Berlin, Not set

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Forli-Cesena

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Naples

Istituto Europeo di Oncologia, Milano, Not set

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele, Milan, Not set

Catholic University of Korea Saint Vincent's Hospital, Suwon-si, Gyeonggi-do

Seoul National University Hospital, Suwon, Gyeonggido

Dong-A University Hospital, Busan, Gyeongsangnam-do

Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do

Seoul National University Hospital, Seoul, Seoul Teugbyeoisi

Severance Hospital, Seoul, Seoul Teugbyeolsi

Haukeland Univeritetssjukehus, Bergen, Hordaland

Oslo Universitetssykehus-Radiumhospitalet, Oslo, Not set

Hospital Clinico Universitarlo de Santiago, Santiago De Compostela, A Coruña

Hospital Clinico Universitarlo de Valencia, València, Valencia

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital Infantil Universitario Niño Jesús, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Virgen del Rocío, Sevilla, Not set

Skånes Universitetssjukhus, Lund, Skåne Län

Karolinska Universitetssjukhuset, Solna, Stockholms Län

The Christie NHS Foundation Trust, Manchester, England

Sarah Cannon Research Institute, London, Not set

Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer

Learn More ›

Personalized Hypoglycemia Outpatient Treatment - a Feasibility Study

NCT07094529

Recruiting

This study will offer two study interventions designed to bring on a mild low blood sugar (capillary blood glucose result 3.0 to 3.8 mmol/L), in order to study the effectiveness of each study participant's personal choice of treatment and first recheck time. The two study interventions that the participant can choose to complete (one or both interventions). Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple ca... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: The Ottawa Hospital, Ottawa, Ontario

Conditions: Type 2 Diabetes (T2DM), Hypoglycemia (Diabetic)

Learn More ›

Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors

NCT05123963

Recruiting

Exercise is well-known to improve skeletal muscle energy metabolism and is an established intervention to improve muscle insulin sensitivity and to counter the development of type 2 diabetes (T2D). However, given the 24h rhythmicity in substrate metabolism previously observed in healthy, lean men and the lack of such rhythmicity in men with insulin-resistance, the investigator hypothesize that appropriate timing of exercise training can maximize the metabolic health effects of exercise. Indeed,... Read More

Gender:

ALL

Ages:

Between 45 years and 75 years

Trial Updated:

07/23/2025

Locations: Centre de recherche du CHUS, Sherbrooke, Quebec

Conditions: Prediabetic State

Learn More ›

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314

Recruiting

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: University of Arizona, Tucson, Arizona +173 locations

University of Arizona, Tucson, Arizona

University of California - San Diego, La Jolla, California

The Angeles Clinic and Research Institute- West Los Angeles, Los Angeles, California

ESC Norris Comprehensive Cancer Center, Los Angeles, California

UCLA Hematology/Oncology, Los Angeles, California

Stanford Cancer Institute - Stanford Cancer Center Palo Alto, Palo Alto, California

Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California

University of Colorado, Anschutz Medical Campus, Aurora, Colorado

UConn Health-Farmington (University of Connecticut Health Center (UCHC)), Farmington, Connecticut

Georgetown University, Washington, District of Columbia

Mayo Clinic Florida, Jacksonville, Florida

University of Miami Health System-Sylvester Comprehensive Cancer Center-Miami, Miami, Florida

Northwestern University - Robert H. Lurie Comprehensive Cancer Center - NMDTI, Chicago, Illinois

The University of Kansas Cancer Center (KUCC) - Westwood, Westwood, Kansas

St. Elizabeth Healthcare - Edgewood, Edgewood, Kentucky

Dana Farber Cancer Institute, Boston, Massachusetts

Washington University School of Medicine, Saint Louis, Missouri

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

Northwell Health Cancer Institute, Lake Success, New York

Columbia University Medical Center, New York, New York

Thomas Jefferson University, Philadelphia, Pennsylvania

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Prisma Health Cancer Institute, Greenville, South Carolina

Spartanburg Regional Healthcare System - Spartanburg Medical Center (SMC), Spartanburg, South Carolina

Sarah Cannon Research Institute: USA/TN, Nashville, Tennessee

University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

UVA Health-UVA Emily Couric Clinical Cancer Center, Charlottesville, Virginia

Swedish Medical Center - Swedish Cancer Institute (SCI) - First Hill Campus, Seattle, Washington

Sanatorio Finochietto, Caba, Buenos Aires

Clínica Adventista Belgrano - Sector Investigación, Caba, Buenos Aires

Instituto Alexander Fleming, Caba, Not set

CEMAIC (Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Córdoba, Not set

Clinica Viedma, Viedma, Not set

Calvary Mater Newcastle Hospital, Waratah, New South Wales

Gallipoli Medical Research Foundation (Greenslopes Private Hospital), Greenslopes, Queensland

Linear Clinical Research, Nedlands, Western Australia

One Clinical Research - Nedlands, Nedlands, Western Australia

Austin Hospital, Heidelberg, Not set

Peter MacCallum Cancer Centre, North Melbourne, Not set

University of Sydney - Melanoma Institute Australia (MIA) - The Poche Centre, Wollstonecraft, Not set

The University of Queensland (UQ) - Princess Alexandra Hospital (PAH), Woolloongabba, Not set

LKH - Universitaetsklinikum Graz, Graz, Not set

Universitätsklinikum St. Pölten, Pölten, Not set

Paracelsus Medizinischen Privatuniversitaet - SALK - Universitaetsklinik fuer Dermatologie - EB-Haus Austria, Salzburg, Not set

Universite Libre de Bruxelles (ULB)-Institut Jules Bordet, Anderlecht, Not set

AZ Sint-Jan Brugge-Oostende AV-Campus Sint-Jan, Brugge, Not set

Universitair Ziekenhuis Brussel, Brussel, Not set

Cliniques Universitaires Saint-Luc - Institut Roi Albert II, Bruxelles, Not set

UZ Leuven, Leuven, Not set

Centro de Pesquisa Clinica em Oncologia - Oncosite, Ijuí, RS

Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa Ltda, Porto Alegre, RS

Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor, Barretos, Not set

Hospital Sirio-Libanes (HSL) - Centro de Oncologia - Brasilia, Brasília, Not set

Centro de Pesquisas Oncologicas (CEPON), Florianópolis, Not set

Oncocentro Sao Carlos Hospital, Fortaleza, Not set

A.C.Camargo Cancer Center - Centro Internacional de Pesquisa (CIPE), Liberdade, Not set

Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, Not set

Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) - Hospital Sao Lucas - Centro de Pesquisa Clinica (CPC), Porto Alegre, Not set

National Cancer Institute, Rio De Janeiro, Not set

Instituto Américas - Instituto de Educação Pesquisa e Gestão em Saúde Oncosite, Rio De Janeiro, Not set

Instituto do Cancer do Estado de Sao Paulo (ICESP), São Paulo, Not set

Hospital 9 de Julho, São Paulo, Not set

Faculdade de Medicina de Sao Jose do Rio Preto-SP (FAMERP) - Hospital de Base (HB) - Centro Integrado de Pesquisa (CIP), São Paulo, Not set

Uni Hospital, Panagyurishte, Not set

Complex Oncology Center - Plovdiv Ltd., Plovdiv, Not set

University Hospital Tsaritsa Yoanna (ISUL) (Queen Giovanna University Hospital), Sofia, Not set

Regina Life Clinic, Sofia, Not set

Princess Margaret Cancer Centre, Toronto, Ontario

Cross Cancer Institute, Edmonton, Not set

Fakultni Nemocnice Hradec Kralove (FNHK) - Klinika Onkologie a Radioterapie, Hradec Králové, Not set

Fakultni Nemocnice Olomouc (FNOL), Olomouc, Not set

Sanatorium Profesora Arenbergera, Praha, Not set

Kobenhavns Universitet - Herlev Hospital (Amtssygehuset i Herlev), Herlev, Not set

Hôpital de la Timone, Marseille, Cedex

Oncopole Claudius Regaud- Institut Universitaire du Cancer de Toulouse, Toulouse, Cedex

Assistance Publique-Hopitaux de Paris (AP-HP) - Hopitaux Universitaires Paris Seine-Saint-Denis - Hopital Avicenne, Bobigny, Not set

Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Ambroise-Pare, Boulogne-Billancourt, Not set

UNICANCER-Centre Francois Baclesse (CFB), Caen, Not set

CHU de Dijon Bourgogne - Hôpital François Mitterrand, Dijon, Not set

Centre Hospitalier Universitaire de Lille (CHU Lille)-Hopital Claude Huriez, Lille, Not set

Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu, Nantes, Not set

Hospital Saint Louis, Paris, Not set

Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud, Pierre-Benite, Not set

Centre Hospitalier Universitaire de Rouen (CHU de Rouen) - Hopital Charles-Nicolle, Rouen, Not set

Hopital Robert Debre, Valence, Not set

Institut Gustave Roussy (IGR) Service de Dermatolgie, Villejuif, Not set

Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM) - Klinik fuer Dermatologie Venerologie und Allergologie - Hauttumorcentrum Charite (HTCC), Berlin, Not set

Universitätsklinikum Carl Gustav Carus, Dresden, Not set

Helios Klinikum Erfurt - Klinik fuer Hautkrankheiten und Allergologie, Erfurt, Not set

Universitaetsklinikum Essen, Essen, Not set

Johann Wolfgang Goethe-Universitaet Frankfurt am Main - Klinik fuer Dermatologie, Venerologie und Allergologie, Frankfurt, Not set

Justus-Liebig-Universitaet Giessen - Klinik fuer Dermatologie und Andrologie, Gießen, Not set

University of Hamburg, Hamburg, Not set

Elbe Kliniken Stade - Hautkrebszentrum Buxtehude, Hamburg, Not set

Universitaetsklinikum Heidelberg (UKHD) - Hautklinik, Heidelberg, Not set

Universitaetsklinikum Leipzig - Klinik fuer Dermatologie, Venerologie und Allergologie, Leipzig, Not set

Johannes Wesling Klinikum Minden, Minden, Not set

LMU Klinikum - Klinik und Poliklinik fur Dermatologie und Allergologie, Munich, Not set

Universitaetsklinikum Tuebingen (UKT) - Zentrum fuer Dermatoonkologie - Hautklinik, Tübingen, Not set

Universitaetsklinikum Wuerzburg - Klinik und Poliklinik fuer Dermatologie Venerologie und Allergologie, Würzburg, Not set

Semmelweis Egyetem Általános Orvostudományi Kar, Budapest, Not set

Pecsi Tudomanyegyetem (PTE) (University of Pecs), Pécs, Not set

Szegedi Tudomanyegyetem (University of Szeged), Szeged, Not set

Istituto Tumori Giovanni Paolo II - Ospedale Oncologico di Bari, Bari, Not set

Humanitas Gavazzeni (Cliniche Gavazzeni S.p.A), Bergamo, Not set

IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" Srl (IRST), Meldola, Not set

Fondazione IRCCS - Istituto Nazionale dei Tumori - Milano, Milano, Not set

Istituto Europeo di Oncologia (IEO) (European Institute of Oncology), Milan, Not set

Istituto Nazionale Tumori (INT) "Fondazione G. Pascale" di Napoli, Napoli, Not set

Istituto Oncologico Veneto (IOV) IRCCS, Padova, Not set

Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia, Perugia, Not set

Azienda Sanitaria Locale di Biella (ASL BI) - Ospedale degli Infermi, Ponderano, Not set

National Cancer Institute Regina Elena, Roma, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Not set

" Azienda Ospedaliera Universitaria Senese - Policlinico Santa Maria Alle Scotte - Clinica Immunoterapia Oncologica", Siena, Not set

Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Torino, Not set

Haukeland University Hospital, Bergen, Not set

Oslo University Hospital, Oslo, Not set

Centrum Onkologii im. Prof. Franciszka Łukaszczyka, Bydgoszcz, Not set

Klinika Onkologii i Radioterapii Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Centrum Medyczne Pratia Poznań - Skorzewo, Skorzewo, Not set

Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków, Warszawa, Not set

L'Institute Oncologique Prof. Dr. Ion Chiricuta (IOCN) (The Oncology Institute Prof. Dr. Ion. Chiricuta), Cluj-Napoca, Not set

Sf Nectarie Oncology Center, Craiova, Not set

Victoria Hospital (Centrul de oncologie Euroclinic SRL) (Centrul De Oncologie Medicala) (Euroclinic Onchology Center), Iaşi, Not set

Universidad de Cantabria (UC) - Hospital Universitario Marques de Valdecilla (HUMV), Santander, Cantabria

Universidad de Murcia - Hospital Universitario Virgen de la Arrixaca (HUVA), El Palmar, Murcia

Complejo Hospitalario Universitario A Coruna (CHUAC), A Coruña, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital Universitario Dexeus, Barcelona, Not set

Hospital Duran i Reynals, Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital Universitario Reina Sofia, Córdoba, Not set

Hospital Universitario Virgen de las Nieves (HUVN), Granada, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Madrid, Madrid, Not set

Hospital Universitario Ramon y Cajal, Madrid, Not set

Universidad Complutense de Madrid (UCM)-Hospital Universitario 12 de Octubre (H12O), Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Not set

Hospital Regional Universitario de Malaga, Málaga, Not set

Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona, Pamplona, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Not set

Hospital Universitario Virgen Macarena, Seville, Not set

Instituto de Investigacion Sanitaria (INCLIVA) (Institute of Health Research Hospital Clinic of Valencia), Valencia, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur), Valencia, Not set

Servicio Aragones de Salud - Hospital Universitario Miguel Servet (HUMS), Zaragoza, Not set

Sahlgrenska Akademin - Institutionen for Kliniska Vetenskaper (Institute of Clinical Sciences), Göteborg, Not set

Lanssjukhuset Ryhov - Onkologiska Kliniken, Jönköping, Not set

Skanes Universitetssjukhus - Lund - Onkologiska Klinik, Lund, Not set

Karolinska Universitetssjukhuset, Stockholm, Not set

Uppsala Universitet - Akademiska Sjukhuset (Uppsala University Hospital), Uppsala, Not set

UniversitaetsSpital Zuerich - Dermatologische Klinik, Zurich, Not set

Memorial Saglik Grubu - Memorial Ankara Hastanesi, Çankaya, Ankara

Medical Park Hastaneler Grubu - I.A.U. VM Medical Park Florya, Antalya, Campus

Medical Park Gaziantep Hastanesi, Şehitkamil, Gaziantep

Memorial Saglik Grubu - Memorial Bahcelievler Hastanesi, Bahçelievler, Istanbul

Ege Universitesi Tip Fakultesi (Ege University Faculty of Medicine), Bornova, İzmir

Izmir Ekonomi Universitesi Medikal Point Hastanesi, Karşıyaka, İzmir

Kanser Enstitusu (Hacettepe University Cancer Institute), Altındağ, Not set

T.C. Saglik Bakanligi - SBU Gulhane Egitim ve Arastirma Hastanesi, Ankara, Not set

Inonu Universitesi - Turgut Ozal Tip Merkezi, Malatya, Not set

Ondokuz Mayis Universitesi (OMU) - Tip Facultesi, Samsun, Not set

Medical Park Seyhan Hastanesi, Seyhan, Not set

T.C. Saglik Bakanligi - Ankara Etlik sehir Hastanesi, Yenimahalle, Not set

Ankara Bilkent City Hospital, Oncology Department, Çankaya, Not set

Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital (AH) - Oncology Centre, Cambridge, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Not set

Sarah Cannon Research Institute (SCRI) - London (SCRI-UK), London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Royal Marsden Hospital - Sutton, Surrey Quays, Not set

Conditions: Advanced Melanoma

Learn More ›

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05421663

Recruiting

This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD19 and CD20, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: City of Hope, Duarte, California +29 locations

City of Hope, Duarte, California

Colorado Blood Cancer Institute, Denver, Colorado

University of Iowa Hospital and Clinics, Iowa City, Iowa

University of Kentucky Medical Center, Lexington, Kentucky

Rutgers Cancer Institute of New Jersey, Piscataway, New Jersey

Levine Cancer Institute, Charlotte, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

St. David's South Austin Medical Center, Austin, Texas

Texas Transplant Institute, San Antonio, Texas

Swedish Cancer Institute, Seattle, Washington

St Vincents Hospital Melbourne, Fitzroy, Not set

The Alfred Hospital, Melbourne, Not set

Fiona Stanley Hospital, Murdoch, Not set

Calvary Mater Newcastle Hospital, Waratah, Not set

Princess Margaret Cancer Centre University Health Network, Toronto, Ontario

Rigshospitalet, Copenhagen, Not set

Odense University Hospital, Odense, Not set

Seoul National University Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Erasmus MC, Rotterdam, Not set

UMC Utrecht, Utrecht, Not set

Hosp Univ Vall D Hebron, Barcelona, Not set

Hosp Clinic de Barcelona, Barcelona, Not set

ICO L'Hospitalet - Hospital Duran i Reynals, Barcelona, Not set

Hosp Univ Fund Jimenez Diaz, Madrid, Not set

University College London Hospitals, London, Not set

The Christie NHS Foundation Trust Christie Hospital, Manchester, Not set

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Learn More ›

Comprehensive Aneurysm Management Trial

NCT04155606

Recruiting

The uncertainty regarding the management of Unruptured Intracranial Aneurysms (UIAs) has not progressed in the last 30 years. The fundamental ethical basis for this study is that physicians should only offer a risky preventive treatment when it has been shown to be beneficial. Before that, such treatment should be offered as an RCT. The CAM trial offers a comprehensive framework, so that all patients confronted with the clinical dilemma can be offered participation. The principal questions to be addressed are : 1. do patients with UIAs, considered for curative treatments, have a better long-term clinical outcome with active treatment or conservative management? 2. when patients are considered ineligible for conservative management, and surgical and endovascular management are both judged reasonable, do patients with UIAs have a better long-term clinical outcome with surgical or endovascular management? The primary hypothesis for patients allocated to at least 2 options, one of which is conservative management is: the 10 year combined neurological morbidity and mortality (mRS\>2) will be reduced from 24% to 16% (beta 80%; alpha 0.048; sample size 961 patients (836 plus 15% losses to FU and cross-overs) with active treatment. This study is designed as a pragmatic, comprehensive way to address the unruptured aneurysm clinical dilemma, combining large simple RCTs whenever patients are judged eligible for more than one management option, or otherwise a registry of each option. All patients with one or more UIAs will be eligible for participation in either a registry or one of the trials. Patients will be followed for 10 years according to a standard of car follow-up schedule. The primary outcome is survival without neurological dependency (mRS\<3) at 10 years. The secondary outcomes are: 1. the incidence of SAH during follow-up and related morbidity and mortality; 2. the morbidity and mortality related to endovascular or surgical treatment of the UIA at one year; 3. overall mortality at 1, 5 and 10 years; 4. overall morbidity (mRS\>2) at 1, 5 and 10 years; 5. length of hospitalization; 6. discharge to location other than home Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: University of Alberta Hospital, Edmonton, Alberta +5 locations

Conditions: Saccular Aneurysm, Intracranial Aneurysm, Unruptured Cerebral Aneurysm

Learn More ›

Pancreatic Cancer Early Detection Consortium

NCT04970056

Recruiting

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Gender:

ALL

Ages:

Between 18 years and 90 years

Trial Updated:

07/23/2025

Locations: Mayo Clinic Arizona, Phoenix, Arizona +59 locations

Mayo Clinic Arizona, Phoenix, Arizona

Honor Health Research Institute, Scottsdale, Arizona

Providence Health and Services, Burbank, California

City of Hope, Duarte, California

UC San Diego Moores Cancer Center, La Jolla, California

Cedars-Sinai Medical Center, Los Angeles, California

UCLA Health, Los Angeles, California

Hoag, Newport Beach, California

UC Irvine Health, Orange, California

UC Davis, Sacramento, California

University of California, San Francisco (UCSF), San Francisco, California

Yale University, New Haven, Connecticut

Mayo Clinic Jacksonville, Jacksonville, Florida

University of Miami, Miami, Florida

Moffitt Cancer Center, Tampa, Florida

Emory University Hospital, Atlanta, Georgia

Illinois CancerCare, Bloomington, Illinois

University of Chicago Medicine, Chicago, Illinois

NorthShore University HealthSystem, Evanston, Illinois

University of Kansas Medical Center, Kansas City, Kansas

Massachusetts General Hospital, Boston, Massachusetts

Umass Memorial Medical Center, Worcester, Massachusetts

University of Michigan, Ann Arbor, Michigan

Beaumont/Corewell Health, Royal Oak, Michigan

University of Nebraska Medical Center, Omaha, Nebraska

Hackensack Meridian Health, Hackensack, New Jersey

Memorial Sloan Kettering Cancer Center, New York, New York

Icahn School of Medicine At Mount Sinai, New York, New York

Columbia University Irving Medical Center, New York, New York

University of Rochester Medical Center, Rochester, New York

White Plains Hospital, White Plains, New York

The Ohio State University, Columbus, Ohio

Oregon Health & Science University, Portland, Oregon

University of Pennsylvania, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center (Upmc), Pittsburgh, Pennsylvania

University of Tennessee Graduate School of Medicine, Knoxville, Tennessee

The University of Texas Southwestern Medical Center, Dallas, Texas

MD Anderson Center, Houston, Texas

Intermountain Health, Saint George, Utah

Huntsman Cancer Institute, Salt Lake City, Utah

University of Virginia, Charlottesville, Virginia

Inova Schar Cancer Institute, Fairfax, Virginia

VCU Massey Comprehensive Cancer Center, Richmond, Virginia

University of Washington, Seattle, Washington

Epworth HealthCare, Richmond, Victoria

British Columbia Cancer Agency, Vancouver, British Columbia

University Health Network, Toronto, Ontario

McGill University Health Centre, Montreal, Quebec

Semmelweis University, Institute of Pancreatic Diseases, Budapest, Not set

Landspitali University Hospital, Reykjavík, Not set

Sheba Medical Center, Ramat Gan, Not set

Azienda Ospedaliera Universitaria Integrata Verona, Verona, Not set

National Cancer Centre Singapore, Singapore, Not set

Hospital Clínic de Barcelona, Barcelona, Not set

Hospital Universitari Arnau De Vilanova, Lleida, Not set

Ramón y Cajal University Hospital, Madrid, Not set

National Cheng Kung University Hospital (NCKUH), Tainan, Taiwan T.O.C.

National Taiwan University Hospital, Taipei, Not set

University of Liverpool, Liverpool, Not set

Conditions: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition

Learn More ›

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277

Recruiting

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: Research Site, Bay Pines, Florida +179 locations

Research Site, Bay Pines, Florida

Research Site, Clearwater, Florida

Research Site, Saint Petersburg, Florida

Research Site, Marietta, Georgia

Research Site, Decatur, Illinois

Research Site, Des Moines, Iowa

Research Site, Leawood, Kansas

Research Site, Lexington, Kentucky

Research Site, Frederick, Maryland

Research Site, Silver Spring, Maryland

Research Site, Towson, Maryland

Research Site, Lincoln, Nebraska

Research Site, Paramus, New Jersey

Research Site, Westbury, New York

Research Site, Canton, Ohio

Research Site, Philadelphia, Pennsylvania

Research Site, Aberdeen, Washington

Research Site, Cordoba, Not set

Research Site, Rosario, Not set

Research Site, Hobart, Not set

Research Site, Woolloongabba, Not set

Research Site, Edegem, Not set

Research Site, Liège, Not set

Research Site, Mechelen, Not set

Research Site, Roeselaere, Not set

Research Site, Blumenau, Not set

Research Site, Fortaleza, Not set

Research Site, Ijui, Not set

Research Site, Itajai, Not set

Research Site, Londrina, Not set

Research Site, Passo Fundo, Not set

Research Site, Porto Alegre, Not set

Research Site, Porto Velho, Not set

Research Site, São Paulo, Not set

Research Site, Burgas, Not set

Research Site, Panagyurishte, Not set

Research Site, Sofia, Not set

Research Site, Kelowna, British Columbia

Research Site, Cambridge, Ontario

Research Site, Toronto, Ontario

Research Site, Baoding, Not set

Research Site, Beijing, Not set

Research Site, Changchun, Not set

Research Site, Changsha, Not set

Research Site, Chongqing, Not set

Research Site, Fuzhou, Not set

Research Site, Guangzhou, Not set

Research Site, Jiamusi, Not set

Research Site, Jinan, Not set

Research Site, Lanzhou, Not set

Research Site, Linyi, Not set

Research Site, Nanchang, Not set

Research Site, Nanjing, Not set

Research Site, Ningbo, Not set

Research Site, Shanghai, Not set

Research Site, Shenyang, Not set

Research Site, Suzhou, Not set

Research Site, Wuhan, Not set

Research Site, Xuzhou, Not set

Research Site, Yantai, Not set

Research Site, Valledupar, Not set

Research Site, Angers, Not set

Research Site, Avignon, Not set

Research Site, Caen, Not set

Research Site, Dijon, Not set

Research Site, La Tronche, Not set

Research Site, Limoges, Not set

Research Site, Nantes CEDEX 1, Not set

Research Site, Paris, Not set

Research Site, Pau Cedex, Not set

Research Site, Toulouse, Not set

Research Site, Tbilisi, Not set

Research Site, Amberg, Not set

Research Site, Bad Saarow, Not set

Research Site, Berlin, Not set

Research Site, Bonn, Not set

Research Site, Essen, Not set

Research Site, Frankfurt am Main, Not set

Research Site, Heilbronn, Not set

Research Site, Immenhausen, Not set

Research Site, Koblenz, Not set

Research Site, Leipzig, Not set

Research Site, München, Not set

Research Site, Oldenburg, Not set

Research Site, Rotenburg, Not set

Research Site, Schweinfurt, Not set

Research Site, Velbert, Not set

Research Site, Würselen, Not set

Research Site, Würzburg, Not set

Research Site, Athens, Not set

Research Site, Peiraias, Not set

Research Site, Thessaloniki, Not set

Research Site, Afula, Not set

Research Site, Beer-Sheva, Not set

Research Site, Hadera, Not set

Research Site, Haifa, Not set

Research Site, Jerusalem, Not set

Research Site, Ramat Gan, Not set

Research Site, Tel Aviv, Not set

Research Site, Tel-Aviv, Not set

Research Site, Candiolo, Not set

Research Site, Lucca, Not set

Research Site, Napoli, Not set

Research Site, Peschiera Del Garda, Not set

Research Site, Pisa, Not set

Research Site, Udine, Not set

Research Site, Verona, Not set

Research Site, Akashi, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Fukuoka-Shi, Not set

Research Site, Hamamatsu-shi, Not set

Research Site, Iwakuni-shi, Not set

Research Site, Izumi-shi, Not set

Research Site, Kashihara-shi, Not set

Research Site, Kobe, Not set

Research Site, Koto-ku, Not set

Research Site, Kurume-shi, Not set

Research Site, Kyoto-shi, Not set

Research Site, Matsuyama-shi, Not set

Research Site, Nankoku-shi, Not set

Research Site, Niigata-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Osakasayama, Not set

Research Site, Sakai-shi, Not set

Research Site, Sendai-shi, Not set

Research Site, Shinagawa-ku, Not set

Research Site, Toyoake-shi, Not set

Research Site, Toyonaka-shi, Not set

Research Site, Jinju-si, Not set

Research Site, Seoul, Not set

Research Site, Kuala Lumpur, Not set

Research Site, Perai, Not set

Research Site, Selangor, Not set

Research Site, Alcabideche, Not set

Research Site, Lisboa, Not set

Research Site, Lisbon, Not set

Research Site, Porto, Not set

Research Site, Bucuresti, Not set

Research Site, Craiova, Not set

Research Site, Iasi, Not set

Research Site, Pitesti, Not set

Research Site, Badalona, Not set

Research Site, Castellón, Not set

Research Site, Granada, Not set

Research Site, Madrid, Not set

Research Site, Málaga, Not set

Research Site, Oviedo, Not set

Research Site, Valencia, Not set

Research Site, Bakirkoy, Not set

Research Site, Izmit, Not set

Research Site, Yüreğir, Not set

Research Site, Çankaya, Not set

Research Site, Blackpool, Not set

Research Site, Hull, Not set

Research Site, Stevenage, Not set

Conditions: Carcinoma, Non-Small Cell Lung

Learn More ›

Prostate Active Surveillance Study

NCT00756665

Recruiting

The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.

Gender:

MALE

Ages:

21 years and above

Trial Updated:

07/23/2025

Locations: Veterans Affairs San Francisco Health Care System, San Francisco, California +10 locations

Conditions: Prostatic Neoplasms

Learn More ›